The category error in psychedelics governance | Manal Al-Hammadi, ALPS Conference 2026

The category error in psychedelics governance | Manal Al-Hammadi, ALPS Conference 2026

Title history
  • The category error in psychedelics governance | Manal Al-Hammadi, ALPS Conference 2026 — observed on 20261112-1654 UTC (YouTube)
🎙 Manal Al-Hammadi 👥 2K 📅 November 12, 2026 ⏱ 57 min 👁 3 📄 original study 🧭 2026-11-12
Available in: English (current) Français

Keywords

category errorpsychedelic-assisted therapycomparative lawgovernance frameworkhealth policy

Summary

In this talk, Manal Al-Hammadi presents her doctoral research on the governance of psychedelic-assisted therapy across nine jurisdictions (Switzerland, Canada, Australia, Germany, Czechia, New Zealand, Oregon, Colorado, Portugal, and the Netherlands) from 2014 to 2026. She argues that a fundamental category error occurs when the authorization of a psychedelic substance is treated as equivalent to governing the entire therapeutic intervention. Drawing on legal analysis and interviews with policymakers, clinicians, researchers, and practitioners, she shows that the current product-focused regulatory frameworks neglect crucial components such as preparation, follow-up, safety reporting, and financing. She identifies common structural barriers, including high costs, inadequate access pathways, inconsistent training, and insufficient adverse event reporting. The talk also highlights variations in national approaches, from medical exception routes to non-medical service models, and notes that no jurisdiction currently finances the complete episode of care. Al-Hammadi proposes a multi-lane governance framework that distinguishes harm reduction, non-medical services, routine medical care, exceptional access, and permanent evidence generation, while ensuring complementarity and transition mechanisms. She concludes by emphasizing that the challenge is not access to a better drug but the creation of a governance framework that recognizes the composite nature of psychedelic-assisted therapy, ensuring responsibility and accountability across all components.

200 words

Critical Evaluation

Value of the Information & Strength of the Argument

The talk offers substantial value by systematically comparing multiple jurisdictions and synthesizing insights from diverse informants. The central argument about the category error is compelling and well-illustrated with concrete examples, such as the FDA’s handling of MDMA safety violations. The use of quotes from informants adds empirical depth. The argumentation follows a logical structure, moving from empirical observations to hypothesis formation and a proposed framework. The distinction between product authorization and intervention governance is clearly articulated and supported by evidence from the interviews. While the research is ongoing and some conclusions are preliminary, the value lies in its innovative perspective and practical implications for policy design.

Scientific Rigor, Source Quality, Title Accuracy

The scientific rigor is high, with a transparent methodology and a careful examination of legal texts and stakeholder interviews. The sources cited include the ALPS Foundation and conference websites, which provide institutional context. The analysis acknowledges limitations, such as the inability to interview informants in certain countries and the recent enactment of some laws. The title is well-aligned with the content, accurately capturing the core concept of a category error in governance. The presenter’s transparency about her professional roles and funding enhances credibility. Overall, the sources are appropriate for the scope, though the non-availability of certain primary documents is a limitation. Public comments were not provided for analysis.

229 words

Title / Content Match

The title accurately reflects the central thesis of the talk, which focuses on identifying a category error in how psychedelics are governed, with detailed evidence from multiple countries.

Quality & Reliability

8/10

The research is based on a comparative legal assessment of nine jurisdictions and 40 planned interviews, though not all informants were accessible. The presenter, a PhD candidate and psychotherapist, transparently declares her professional background and funding. The analysis is structured and evidence-based, but some parts rely on legal reading without practical implementation verification (e.g., Czechia). The strong reliance on interviews and legal sources adds credibility, but the lack of access to certain informants limits representativeness.

Chapters

Cited Sources

  • ALPS Foundation — Non-profit organization hosting the conference and promoting psychedelic science.
  • ALPS Conference 2026 — Official conference page where the talk was recorded and programme details are available.
  • ALPS LinkedIn company page — Company page of the organizing entity, providing background information.

Contribution & Novelties

The original contribution of this research is the identification of a systematic category error in psychedelics governance: the authorization of a medicinal product is mistakenly treated as equivalent to the governance of the entire therapeutic intervention. This perspective is novel in the field of psychedelic policy and offers a multi-lane governance framework that has not been implemented anywhere but provides a new heuristic for policymakers. The study combines legal analysis with stakeholder interviews, producing a rich dataset and actionable insights.

Pour aller plus loin :

132 words

Radar Profile

The radar profile is balanced, with high scores across all dimensions, reflecting a well-researched and technically strong presentation. The highest score is in quantity of information, indicating a dense and comprehensive treatment of the subject, while quality and reliability are also notably high, suggesting scholarly rigor.

Reliability 8/10